Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

137

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: alpelisib
DRUG: placebo
DRUG: nab-paclitaxel

Sponsor

Novartis Pharmaceuticals